Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open label study to assess the suitability of CPX-351 as first intensive therapy
in elderly (age ≥60 years) patients with AML. Patients may have received prior AML treatment
with non-intensive regimens, e.g. hypomethylating agents, low dose Ara C or lenolidomide, but
may not have received intensive AML treatment with anthracyclines and/or cytarabine prior to
enrollment on this trial. The outcome of elderly patients following intensive treatment with
CPX-351 will be measured by clinical endpoints for efficacy and safety and by
biological/functional response.